歷年發表著作 / Publication (2024/04/06 更新)

Publication：

• Pubmed: Full Text

Representative works (in English):

Sjögren's syndrome 修格蘭氏症

1. Hong-Chun Lin, Chien-Ming Yen, Wei-Sheng Chen, Chih-Chien Hsu, Yen-Ying Kung, Jin-Huang Wu, Yu-Ting Su, Kuo-Feng Chen, Hsin-Yuan Chen, Chien-Min Lien, Ming-Jen Wang, Ching-Mao Chang*. Unveiling the Age-Related Dynamics in Sjögren's Syndrome: Insights from Heart Rate Variability and Autonomic Function. International Journal of Rheumatic Diseases. 2024 (SCI, 2023 IF=2.5)
2. Ching-Mao Chang, Po-Chang Wu, Jr-Rung Lin, Yeong-Jian Jan Wu, Shu-Fen Lo, Yin-Tzu Hsue, Joung-Liang Lan, Tai-Long Pan, Yu-Ting Wu, Kuang-Hui Yu*, Yau-Huei Wei*, Hen-Hong Chang*. Herbal Formula SS-1 Increases Tear Secretion for Sjögren’s Syndrome. Frontiers in Pharmacology. 2021 (SCI, 2021 IF= 5.810)
3. Tieh-Cheng Fu, Yen-Ying Kung, Jr-Rung Lin, Ching-Mao Chang*. Editorial: Objective Diagnosis and Management of Immune-mediated Rheumatic Diseases. Frontiers in Medicine. 2023 (SCI, 2022 IF= 5.058)
4. Hsin-Yuan Chen, Jin-Huang Wu, Hong-Chun Lin, Yu-Ting Su, Chien-Ming Yen, Ching-Mao Chang*. Commentary: Efficacy and Safety of Acupuncture on Symptomatic Improvement in Primary Sjögren’s Syndrome – A Randomized Controlled Trial. Frontiers in Medicine. 2023 (SCI, 2022 IF= 5.058)
5. 孔德馨，蘇郁婷，林虹均，吳璟凰，張清貿*. 乾燥症之中醫舌脈持續評估病例報告. 中醫藥雜誌. 2023
6. Gilbert Aaron Lee#, Ching-Mao Chang#, Ying Chieh Wu, Ruo-yu Ma, Cheng-Yu Chen, Yin-Tzu Hsue, Nan-Shih Liao*, Hen-Hong Chang*. Chinese herbal medicine SS-1 inhibits T cell activation and ameliorates TH responses in Sjögren’s syndrome. Journal of the Formosan Medical Association. 2020 (SCI, 2020 IF= 3.008，共同第一作者)
7. Ching-Mao Chang, Hsueh-Ting Chu, Yau-Huei Wei, Fang-Pey Chen, Shengwen Wang, Po-Chang Wu, Hung-Rong Yen, Tzeng-Ji Chen* and Hen-Hong Chang*: The Core Pattern Analysis on Chinese Herbal Medicine for Sjögren's syndrome: A Nationwide Population-Based Study. Scientific Reports. 2015 (SCI, 2014 IF= 5.578) 
8. 黃偉勝，林虹均，曾偉婷，張清貿*. 中藥治療修格蘭氏症候群合併系統性紅斑狼瘡病例報告. 中醫藥雜誌. 2020
9. 陳國豐，曾偉婷，林虹均，張清貿*. 中藥緩解修格蘭氏症合併橋本氏甲狀腺炎之病例報告. 中醫藥研究論叢. 2020
10. Ching-Mao Chang, Hsueh-Ting Chu, Yau-Huei Wei, Fang-Pey Chen, Shengwen Wang, Po-Chang Wu, Hung-Rong Yen, Tzeng-Ji Chen*, Hen-Hong Chang*, The Core Pattern of Chinese Herbal Medicines for Sjögren's Syndrome in Taiwan from National Health Insurance Research Database between year 2002 to 2011, 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2014

Systemic Lupus Erythematosus 紅斑性狼瘡

1. Hsiao-Tien Chen†, Chien-Hsueh Tung†, Ben-Hui Yu, Ching-Mao Chang*, Yi-Chun Chen*. Renal and survival benefits of seventeen prescribed Chinese herbal medicines against oxidative-inflammatory stress in systemic lupus erythematosus patients with chronic kidney disease: A real-world longitudinal study. Frontiers in Pharmacology. 2024 (SCI, 2023 IF= 5.6)
2. Ching-Mao Chang, Jr-Rung Lin, Tieh-Cheng Fu. Associations between sarcopenia, heart failure and myocardial infarction in patients with systemic lupus erythematosus and rheumatoid arthritis. Frontiers in Medicine. 2022 (SCI, 2022 IF= 5.058)
3. 馬碩煒，林虹均，曾偉婷，張清貿*. 中藥治療系統性紅斑性狼瘡合併狼瘡腎炎病例報告. 中醫藥雜誌. 2021
4. Wei-Ting Tseng, Po-Hsuan Shih, Hong-Chun Lin, Pei-Wen Wu, Yen-Ying Kung, Ching-Mao Chang*. Stabilityof a Lupus Nephritis Case after One Year of Integrated Therapy. EC Gastroenterology and Digestive System. 2020 (本論文為先前發表病例報告之後續追蹤[研究發表][臨床病例報告] 中西醫整合治療紅斑性狼瘡腎炎病例報告，Integrated Therapy Improve Urinary Total Protein in Patients with Lupus Nephritis: A Case Report)
5. Pei-Wen Wu#, Po-Hsuan Shih#, Yen-Ying Kung, Fang-Pey Chen, Ching-Mao Chang*. Integrated Therapy Improve Urinary Total Protein in Patients with Lupus Nephritis: A Case Report. Complementary Therapies in Medicine. 2018 (SCI, 2016 IF= 2.013) (本論文後續追蹤持續報告為Stabilityof a Lupus Nephritis Case after One Year of Integrated Therapy. EC Gastroenterology and Digestive System. 2020)
6. Ching-Mao Chang, Po-Chang Wu, Jen-Huai Chiang, Yau-Huei Wei, Fang-Pey Chen, Tzeng-Ji Chen, Tai-Long Pan, Hung-Rong Yen* and Hen-Hong Chang*. Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study. Journal of Ethnopharmacology. 2017 (SCI, 2015 IF= 3.055)
7. Hen-Hong Chang, Shue-Fen Luo, Yin-Tzu Hsue, Ching-Mao Chang, Tzung-Yan Lee, Ming-Ling Hsu, Yu-Chuen Huang, Yu-Jen Chen. Modulation of Endothelial Injury Biomarkers by Traditional Chinese Medicine LC in Systemic Lupus Erythematosus Patients Receiving Standard Treatments. Scientific Reports. 2016 (SCI, 2015 IF=5.578)
8. Ching-Mao Chang, Wen-Hsiang Wu, Benjamin Ing-Tiau Kuo, Tzung-Yan Lee, Chia-Yu Liu, Hen-Hong Chang*: Using A Questionnaire among Patient, Resident Doctor and Senior Supervisor: Are their Answers the Same? Complementary Therapies in Medicine. 2014 (SCI, 2013 IF=2.216)
9. Ching-Mao Chang, Yi-Chung Ling, Po-Chang Wu, Hen-Hong Chang*, The Change of Symptoms in the Treatment of Traditional Chinese Medicine for Systemic Lupus Erythematosus, 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2014
10. Ching-Mao Chang, Benjamin Ing-Tiau Kuo, Wen-Hsiang Wu, Chia-Yu Liu, Hen-Hong Chang*: The Consistency Among Patients, Resident Doctor and Senior Supervisor in using a Traditional Chinese Medicine Questionnaire. 10th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2011

Rheumatoid arthritis 類風濕關節炎

1. Tieh-Cheng Fu, Chun-Pai Yang, Ching-Mao Chang*. Exploring the Link Between Thyrotoxicosis and Cognitive Decline in Older Adults. JAMA Internal Medicine. 2024 (SCI, 2023 IF=39)
2. Ming-Cheng Huang, Fu-Tzu Paic, Che-Chen Lind, Ching-Mao Chang, Hen-Hong Chang, Yu-Chen Lee, Mao-Feng Sun, Hung-Rong Yen*. Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study. Journal of Ethnopharmacology. 2015 (SCI, 2014 IF= 2.998)

Thyroid Disease/Hashimoto thyroiditis 甲狀線疾病/橋本氏甲狀腺炎

1. Tieh-Cheng Fu, Jr-Rung Lin, Ching-Mao Chang*. Association between herpes simplex virus II and rheumatoid arthritis: a population-based study. JCR: Journal of Clinical Rheumatology. 2023 (SCI, 2023 IF=3.4)
2. 陳國豐，曾偉婷，林虹均，張清貿*. 中藥緩解修格蘭氏症合併橋本氏甲狀腺炎之病例報告. 中醫藥研究論叢. 2020

Ankylosing Spondylitis 僵直性脊椎炎

1. 吳育瑜，顏見明，林虹均，陳國豐，張清貿*. 中藥治療僵直性脊椎炎之病例報告. 中醫藥研究論叢. 2023

Polymyositis / Dermatomyositis 多發性肌炎 / 皮肌炎

1. Ching-Mao Chang#, Po-Hsuan Shih#, Tzeng-Ji Chen, Wen-Chao Ho*, Chun-Pai Yang*. Integrated Therapy Decreases the Mortality of Patients with Polymyositis and Dermatomyositis: A Taiwan-wide Population-Based Retrospective Study. Journal of Ethnopharmacology. 2019, 236: 70-81 (SCI, 2018 IF= 3.414)

Chronic hepatitis C 慢性C型肝炎

1. Ching-Mao Chang*. Integrated Therapy for Chronic Hepatitis in Taiwan. EC Gastroenterology and Digestive System. 2018 
2. Fang-Pey Chen, Ching-Mao Chang, Ta-Peng Wu, Jen-Lin Yang, Yen-Ying Kung, Yi-Hsiang Huang, Chien-Wei Su, Keng-Hsin Lan, Shu-Chiung Chiang and Shinn-Jang Hwang*. Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. Journal of Ethnopharmacology. 2017 (SCI, 2015 IF= 3.055)

Parkinson's Disease 帕金森氏症

1. Ching-Chi Hsu, Shiow-Ing Wang, Hong-Chun Lin, Eric S. Lin, Fan-Pei Yang, Ching-Mao Chang*, James Cheng-Chung Wei*. Difference of CSF biomarkers and neuropsychiatric symptoms profiles among Normal cognition, Mild cognitive impairment, and Dementia patients. International Journal of Molecular Sciences. 2024 (SCI, 2023 IF= 5.6)
2. Fang-Pey Chen, Ching-Mao Chang, Jing-Huei Shiu, Jen-Hwey Chiu, Ta-Peng Wu, Jen-Lin Yang, Yen-Ying Kung, Fun-Jou Chen, Chang-Ming Chern* and Shinn-Jang Hwang*: A Clinical Study of Integrating Acupuncture and Western Medicine in Treating Patients with Parkinson's Disease. The American Journal of Chinese Medicine. 2015 (SCI, 2014 IF= 2.625) 

Neuropsychiatric disorders 神經精神疾病

1. Tieh-Cheng Fu, Juei-Chao Chen, Ching-Mao Chang*. Ferritin levels as a potential predictive clinical marker: Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders (Brain. Behav. Immun. 2023 Aug 28:114:255–261. doi: 10.1016/j.bbi.2023.08.024). Brain, Behavior, and Immunity. 2023  (SCI, 2023 IF=15.1)
2. Hsien-Yin Liao, Ching-Mao Chang, Yi-Wen Lin*, Kuan-Pin Sue*. When East Meets West in Clinical Trial Designs! Reply to “Discussion regarding the establishment of pain- and depression-specific acupoints in a randomized controlled trial with crossover design”. Brain, Behavior, and Immunity. 2023  (SCI, 2023 IF=15.1)
3. Ting-Bin Chen, Ching-Mao Chang, Cheng-Chia Yang, I-Ju Tsai, Cheng-Yu Wei*, Hao-Wen Yang*, Chun-Pai Yang*. The Neuroimmunological Effect of Vitamin D on Neuropsychiatric Long-COVID Syndrome. Nutrients. 2023 (SCI, 2023 IF=5.9)
4. Chun-Pai Yang#, Cheng-Chia Yang#, I-Ju Tsai, Tsung-Hsing Lin, Ya-Ling Chiou*, Hsiao-Fen Wang*, Ching-Mao Chang*, Kuang-Hway Yih. The immediate effects of lavender-based essential oil inhalation on subsequent polysomnography in patients with poor sleep quality. Journal of the Chinese Medical Association. 2023 (SCI, 2022 IF= 3.396)
5. Tsung-Hsing Lin#, Cheng-Chia Yang#, Shih-Yu Lee, Ching-Mao Chang, I-Ju Tsai, Cheng-Yu Wei*, Chun-Pai Yang*. The effect of bright light therapy on migraine with sleep disturbance: protocol for a prospective, observational cohort study. Frontiers in Aging Neuroscience. 2023 (SCI, 2022 IF= 5.702)

Heart failure 心臟衰竭

1. Tieh-Cheng Fu, Chaur-Chin Chen, Ching-Mao Chang*, Hen-Hong Chang, Hsueh-Ting Chu*. Analysis of Exercise-induced Periodic Breathing Using an Autoregressive Model and the Hilbert-Huang Transform. Computational and Mathematical Methods in Medicine. 2018 (SCI, 2018 IF= 1.563)
2. Tieh-Cheng Fu, Yi-Chung Lin, Ching-Mao Chang, Wei-Ling Chou, Pei-Hsun Yuan, Min-Hui Liu, Chao-Hung Wang, Juei-Chao Chen, Hen-Hong Chang* and Tai-Long Pan. Validation of a new simple scale to measure symptoms in heart failure from traditional Chinese medicine view: a cross-sectional questionnaire study. BMC Complementary and Alternative Medicine, 2016, 16:342 (SCI, 2015 IF=1.987)

Nutrients, Polyunsaturated fatty acid (PUFA), Omega-3 and EPA (Eicosapentaenoic acid) 營養素、多元不飽和脂肪酸、Omega-3及EPA

1. Ting-Bin Chen, Cheng-Chia Yang, I-Ju Tsai, Hao-Wen Yang, Yung-Chu Hsu*, Ching-Mao Chang*, Chun-Pai Yang*. Neuroimmunological effects of omega-3 fatty acids on migraine: A review. Frontiers in Neurology. 2024 (SCI, 2023 IF= 3.4)
2. Hsueh-Fang Wang, Wen-Chun Liu, Halliru Zailani, Cheng-Chia Yang, Ting-Bin Chen, Ching-Mao Chang, I-Ju Tsai, Chun-Pai Yang*, Kuan-Pin Su*. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain, Behavior, and Immunity. 2024 (SCI, 2023 IF=15.1)
3. Yu Aoh, Tsung-Wei Hou, Cheng-Chia Yang, Ching-Mao Chang, I-Ju Tsai, Chin-Wen Cheng*, Chun-Pai Yang* Update on gepants for the treatment of chronic migraine. Journal of the Chinese Medical Association. 2024 (SCI, 2022 IF= 3.0)
4. Tsung-Hsing Lin#, Cheng-Chia Yang#, Shih-Yu Lee, Ching-Mao Chang, I-Ju Tsai, Cheng-Yu Wei*, Chun-Pai Yang*. The effect of bright light therapy on migraine with sleep disturbance: protocol for a prospective, observational cohort study. Frontiers in Aging Neuroscience. 2023 (SCI, 2022 IF= 5.702)
5. Ting-Bin Chen, Ching-Mao Chang, Cheng-Chia Yang, I-Ju Tsai, Cheng-Yu Wei*, Hao-Wen Yang*, Chun-Pai Yang*. The Neuroimmunological Effect of Vitamin D on Neuropsychiatric Long-COVID Syndrome. Nutrients. 2023 (SCI, 2023 IF=5.9)
6. Chun-Pai Yang, Ching-Mao Chang, Cheng-Chia Yang, Carmine M. Pariante, Kuan-Pin Su*. Long COVID and Long Chain Fatty Acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain, Behavior, and Immunity. 2022 (SCI, 2022 IF=19.227)

Long-COVID Syndrome 長新冠疾病

1. Chun-Pai Yang, Ching-Mao Chang, Cheng-Chia Yang, Carmine M. Pariante, Kuan-Pin Su*. Long COVID and Long Chain Fatty Acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain, Behavior, and Immunity. 2022 (SCI, 2022 IF=19.227)
2. Tieh-Cheng Fu, Juei-Chao Chen, Ching-Mao Chang*. Ferritin levels as a potential predictive clinical marker: Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders (Brain. Behav. Immun. 2023 Aug 28:114:255–261. doi: 10.1016/j.bbi.2023.08.024). Brain, Behavior, and Immunity. 2023  (SCI, 2023 IF=15.1)
3. Ting-Bin Chen, Ching-Mao Chang, Cheng-Chia Yang, I-Ju Tsai, Cheng-Yu Wei*, Hao-Wen Yang*, Chun-Pai Yang*. The Neuroimmunological Effect of Vitamin D on Neuropsychiatric Long-COVID Syndrome. Nutrients. 2023 (SCI, 2023 IF=5.9)

Gastrointestinal diseases 消化道疾病

1. Chien-Ming Yen, Tieh-Cheng Fu, Ching-Mao Chang*. Methods, Complications, and Outcomes in a Randomized Clinical Trial of Electroacupuncture After Colorectal Cancer Surgery. JAMA Surgery. 2023 (SCI, 2022 IF= 16.7)
2. Hong-Chun Lin, Chien-Ming Yen, Kuo-Feng Chen, Yen-Ying Kung, Yung-Hung Hsieh, Ching-Mao Chang*. The banned herbal medicine induced liver injury in Taiwan. Hepatology International. 2022 (SCI, 2022 IF= 9.029)
3. 吳珮雯，施柏瑄，林虹均，曾偉婷，張清貿*. 臺灣本土治療消化性潰瘍疾病之整合醫學研究回顧. 中醫藥新知. 2020
4. Yi-Ting Kuo, Hou-Hsun Liao, Jen-Huai Chiang, Bor-Chyuan Chen, Ching-Mao Chang, Ming-Hsien Yeh, Tung-Ti Chang, Mao-Feng Sun, Chia-Chou Yeh, Hung-Rong Yen*. Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients with Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study. Integrative Cancer Therapies. 2017 (SCI, 2016 IF= 1.923)
5. Ching-Ying Huang, Wan-Yu Lai, Mao-Feng Sun, Che-Chen Lin, Bor-Chyuan Chen, Ching-Mao Chang, Hong-Jen Lin,  Chung-Hsien Yang, Kuo-Chin Huang, Hung-Rong Yen*. Prescription Patterns of Traditional Chinese Medicine for Peptic Ulcer Disease in Taiwan: A Nationwide Population-based Study. Journal of Ethnopharmacology. 2015 (SCI, 2014 IF= 2.998) 

Migraine 偏頭痛

1. Ting-Bin Chen, Cheng-Chia Yang, I-Ju Tsai, Hao-Wen Yang, Yung-Chu Hsu*, Ching-Mao Chang*, Chun-Pai Yang*. Neuroimmunological effects of omega-3 fatty acids on migraine: A review. Frontiers in Neurology. 2024 (SCI, 2023 IF= 3.4)
2. Hsueh-Fang Wang, Wen-Chun Liu, Halliru Zailani, Cheng-Chia Yang, Ting-Bin Chen, Ching-Mao Chang, I-Ju Tsai, Chun-Pai Yang*, Kuan-Pin Su*. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain, Behavior, and Immunity. 2024 (SCI, 2023 IF=15.1)
3. Yu Aoh, Tsung-Wei Hou, Cheng-Chia Yang, Ching-Mao Chang, I-Ju Tsai, Chin-Wen Cheng*, Chun-Pai Yang* Update on gepants for the treatment of chronic migraine. Journal of the Chinese Medical Association. 2024 (SCI, 2022 IF= 3.0)
4. Tsung-Hsing Lin#, Cheng-Chia Yang#, Shih-Yu Lee, Ching-Mao Chang, I-Ju Tsai, Cheng-Yu Wei*, Chun-Pai Yang*. The effect of bright light therapy on migraine with sleep disturbance: protocol for a prospective, observational cohort study. Frontiers in Aging Neuroscience. 2023 (SCI, 2022 IF= 5.702)
5. Ching-Mao Chang#, Chun-Pai Yang#, Cheng-Chia Yang, Po-Hsuan Shih, Shuu-Jiun Wang*. Evidence of Potential Mechanisms of Acupuncture from FunctionalMRI Data for Migraine Prophylaxis. Current Pain and Headache Reports. 2021 (SCI, 2021 IF= 3.494)
6. Chun-Pai Yang, Chih-Sung Liang, Ching-Mao Chang, Cheng-Chia Yang, Po-Hsuan Shih, Yun-Chain Yau, Kuo-Tung Tang*, Shuu-Jiun Wang*. A Comparison of Efficacy and Tolerability of New Classes of Migraine-Specific Treatments: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. JAMA Network Open. 2021 (SCI, 2021 IF= 8.48)
7. Chun-Pai Yang#, Bing-Yan Zeng#, Ching-Mao Chang, Po-Hsuan Shih, Cheng-Chia Yang, Ping-Tao Tseng*, Shuu-Jiun Wang*. Comparative effectiveness and tolerability of the pharmacology of monoclonal antibody reacting to calcitonin gene-related peptide for the prevention of chronic migraine: A network meta-analysis of randomized controlled trials. Neurotherapeutics. 2021 (SCI, 2021 IF= 7.620)
8. Chun-Pai Yang#, Kuo-Ting Huang#, Ching-Mao Chang, Cheng-Chia Yang, Shuu-liun Wang*. Acute Treatment of Migraine: What has changed in pharmacotherapies? Neurology India. 2021 (SCI, 2021 IF= 2.117)
9. Pin-Chung Huang, Fu-Chi Yang, Ching-Mao Chang, Chun-Pai Yang*. Chapter 4: Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. Update on Emerging Treatments for Migraine, Elsevier: Progress in Brain Research (ISBN: 978-0-12-821108-3), 2020(255):P.99-P.121

Representative works (in Chinese):

1. 孔德馨，蘇郁婷，林虹均，吳璟凰，張清貿*. 乾燥症之中醫舌脈持續評估病例報告. 中醫藥雜誌. 2023
2. 吳育瑜，顏見明，林虹均，陳國豐，張清貿*. 中藥治療僵直性脊椎炎之病例報告. 中醫藥研究論叢. 2023
3. 洪慈瑩，陳國豐，林虹均，顏見明，張清貿*. 滋陰降火及清熱利溼治療菊地氏病. 中醫藥研究論叢. 2023
4. 馬碩煒，林虹均，曾偉婷，張清貿*. 中藥治療系統性紅斑性狼瘡合併狼瘡腎炎病例報告. 中醫藥雜誌. 2021
5. 吳璟凰，林虹均，陳國豐，張清貿*. 針刺治療肌少症之文獻回顧與展望. 台灣骨鬆肌少關節防治學會 TBMJ. 2021
6. 吳珮雯，施柏瑄，林虹均，曾偉婷，張清貿*. 臺灣本土治療消化性潰瘍疾病之整合醫學研究回顧. 中醫藥新知. 2020
7. 黃偉勝，林虹均，曾偉婷，張清貿*. 中藥治療修格蘭氏症候群合併系統性紅斑狼瘡病例報告. 中醫藥雜誌. 2020
8. 陳國豐，曾偉婷，林虹均，張清貿*. 中藥緩解修格蘭氏症合併橋本氏甲狀腺炎之病例報告. 中醫藥研究論叢. 2020
9. 張清貿#, 施柏瑄#, 楊仕哲*. 心腦主神明學說的沿革. 中醫藥雜誌. 2017, 28(1): 2801001
10. 施柏瑄#, 洪國棟#, 林奕中, 張清貿*. 僵直性脊椎炎之中醫藥文獻回顧. 中醫藥研究論叢. 2016, 19(2):99-112
11. 張清貿, 施柏瑄, 朱學亭, 陳方佩. 該如何理解「證」？- 中醫證型現代研究的定性與定量, 臨床醫學. 2014 (73)：189-195
12. 張清貿, 侯庭鏞, 朱學亭, 李佳橙, 張永賢* 附子在溫經散寒及清熱瀉火劑之數學模式表現 (A mathematical method to differentiate the effects of “Aconitum carmichaeli Debx” in different prescriptions). Mid-Taiwan Journal of Medicine. 2008 13(3): 152-157

A: Referred Pape

1. Ting-Bin Chen, Cheng-Chia Yang, I-Ju Tsai, Hao-Wen Yang, Yung-Chu Hsu*, Ching-Mao Chang*, Chun-Pai Yang*. Neuroimmunological effects of omega-3 fatty acids on migraine: A review. Frontiers in Neurology. 2024 (SCI, 2023 IF= 3.4)
2. Ching-Chi Hsu, Shiow-Ing Wang, Hong-Chun Lin, Eric S. Lin, Fan-Pei Yang, Ching-Mao Chang*, James Cheng-Chung Wei*. Difference of CSF biomarkers and neuropsychiatric symptoms profiles among Normal cognition, Mild cognitive impairment, and Dementia patients. International Journal of Molecular Sciences. 2024 (SCI, 2023 IF= 5.6)
3. Hsueh-Fang Wang, Wen-Chun Liu, Halliru Zailani, Cheng-Chia Yang, Ting-Bin Chen, Ching-Mao Chang, I-Ju Tsai, Chun-Pai Yang*, Kuan-Pin Su*. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain, Behavior, and Immunity. 2024 (SCI, 2023 IF=15.1)
4. Yu Aoh, Tsung-Wei Hou, Cheng-Chia Yang, Ching-Mao Chang, I-Ju Tsai, Chin-Wen Cheng*, Chun-Pai Yang* Update on gepants for the treatment of chronic migraine. Journal of the Chinese Medical Association. 2024 (SCI, 2022 IF= 3.0)
5. Hong-Chun Lin, Chien-Ming Yen, Wei-Sheng Chen, Chih-Chien Hsu, Yen-Ying Kung, Jin-Huang Wu, Yu-Ting Su, Kuo-Feng Chen, Hsin-Yuan Chen, Chien-Min Lien, Ming-Jen Wang, Ching-Mao Chang*. Unveiling the Age-Related Dynamics in Sjögren's Syndrome: Insights from Heart Rate Variability and Autonomic Function. International Journal of Rheumatic Diseases. 2024 (SCI, 2023 IF=2.5)
6. Tieh-Cheng Fu, Chun-Pai Yang, Ching-Mao Chang*. Exploring the Link Between Thyrotoxicosis and Cognitive Decline in Older Adults. JAMA Internal Medicine. 2024 (SCI, 2023 IF=39)
7. Hsiao-Tien Chen†, Chien-Hsueh Tung†, Ben-Hui Yu, Ching-Mao Chang*, Yi-Chun Chen*. Renal and survival benefits of seventeen prescribed Chinese herbal medicines against oxidative-inflammatory stress in systemic lupus erythematosus patients with chronic kidney disease: A real-world longitudinal study. Frontiers in Pharmacology. 2024 (SCI, 2023 IF= 5.6)
8. Tieh-Cheng Fu, Juei-Chao Chen, Ching-Mao Chang*. Ferritin levels as a potential predictive clinical marker: Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders.  Brain, Behavior, and Immunity. 2023 (SCI, 2023 IF=15.1)
9. Tieh-Cheng Fu, Jr-Rung Lin, Ching-Mao Chang*. Association between herpes simplex virus II and rheumatoid arthritis: a population-based study. JCR: Journal of Clinical Rheumatology. 2023 (SCI, 2023 IF=3.4)
10. Ting-Bin Chen, Ching-Mao Chang, Cheng-Chia Yang, I-Ju Tsai, Cheng-Yu Wei*, Hao-Wen Yang*, Chun-Pai Yang*. The Neuroimmunological Effect of Vitamin D on Neuropsychiatric Long-COVID Syndrome. Nutrients. 2023 (SCI, 2023 IF=5.9)
11. Hsien-Yin Liao, Ching-Mao Chang, Yi-Wen Lin*, Kuan-Pin Sue*. When East Meets West in Clinical Trial Designs! Reply to “Discussion regarding the establishment of pain- and depression-specific acupoints in a randomized controlled trial with crossover design”. Brain, Behavior, and Immunity. 2023  (SCI, 2023 IF=15.1)
12. 孔德馨，蘇郁婷，林虹均，吳璟凰，張清貿*. 乾燥症之中醫舌脈持續評估病例報告. 中醫藥雜誌. 2023
13. 吳育瑜，顏見明，林虹均，陳國豐，張清貿*. 中藥治療僵直性脊椎炎之病例報告. 中醫藥研究論叢. 2023
14. 洪慈瑩，陳國豐，林虹均，顏見明，張清貿*. 滋陰降火及清熱利溼治療菊地氏病. 中醫藥研究論叢. 2023
15. Chien-Ming Yen, Tieh-Cheng Fu, Ching-Mao Chang*. Methods, Complications, and Outcomes in a Randomized Clinical Trial of Electroacupuncture After Colorectal Cancer Surgery. JAMA Surgery. 2023 (SCI, 2022 IF= 16.7)
16. Chun-Pai Yang#, Cheng-Chia Yang#, I-Ju Tsai, Tsung-Hsing Lin, Ya-Ling Chiou*, Hsiao-Fen Wang*, Ching-Mao Chang*, Kuang-Hway Yih. The immediate effects of lavender-based essential oil inhalation on subsequent polysomnography in patients with poor sleep quality. Journal of the Chinese Medical Association. 2023 (SCI, 2022 IF= 3.396)
17. Tieh-Cheng Fu, Yen-Ying Kung, Jr-Rung Lin, Ching-Mao Chang*. Editorial: Objective Diagnosis and Management of Immune-mediated Rheumatic Diseases. Frontiers in Medicine. 2023 (SCI, 2022 IF= 5.058)
18. Hsin-Yuan Chen, Jin-Huang Wu, Hong-Chun Lin, Yu-Ting Su, Chien-Ming Yen, Ching-Mao Chang*. Commentary: Efficacy and Safety of Acupuncture on Symptomatic Improvement in Primary Sjögren’s Syndrome – A Randomized Controlled Trial. Frontiers in Medicine. 2023 (SCI, 2022 IF= 5.058)
19. Tsung-Hsing Lin#, Cheng-Chia Yang#, Shih-Yu Lee, Ching-Mao Chang, I-Ju Tsai, Cheng-Yu Wei*, Chun-Pai Yang*. The effect of bright light therapy on migraine with sleep disturbance: protocol for a prospective, observational cohort study. Frontiers in Aging Neuroscience. 2023 (SCI, 2022 IF= 5.702)
20. Ching-Mao Chang, Jr-Rung Lin, Tieh-Cheng Fu. Associations between sarcopenia, heart failure and myocardial infarction in patients with systemic lupus erythematosus and rheumatoid arthritis. Frontiers in Medicine. 2022 (SCI, 2022 IF= 5.058)
21. Hong-Chun Lin, Chien-Ming Yen, Kuo-Feng Chen, Yen-Ying Kung, Yung-Hung Hsieh, Ching-Mao Chang*. The banned herbal medicine induced liver injury in Taiwan. Hepatology International. 2022 (SCI, 2022 IF= 9.029)
22. Chun-Pai Yang, Ching-Mao Chang, Cheng-Chia Yang, Carmine M. Pariante, Kuan-Pin Su*. Long COVID and Long Chain Fatty Acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain, Behavior, and Immunity. 2022 (SCI, 2022 IF=19.227)
23. Ching-Mao Chang, Po-Chang Wu, Jr-Rung Lin, Yeong-Jian Jan Wu, Shu-Fen Lo, Yin-Tzu Hsue, Joung-Liang Lan, Tai-Long Pan, Yu-Ting Wu, Kuang-Hui Yu*, Yau-Huei Wei*, Hen-Hong Chang*. Herbal Formula SS-1 Increases Tear Secretion for Sjögren’s Syndrome. Frontiers in Pharmacology. 2021 (SCI, 2021 IF= 5.810)
24. Ching-Mao Chang#, Chun-Pai Yang#, Cheng-Chia Yang, Po-Hsuan Shih, Shuu-Jiun Wang*. Evidence of Potential Mechanisms of Acupuncture from FunctionalMRI Data for Migraine Prophylaxis. Current Pain and Headache Reports. 2021 (SCI, 2021 IF= 3.494)
25. Chun-Pai Yang, Chih-Sung Liang, Ching-Mao Chang, Cheng-Chia Yang, Po-Hsuan Shih, Yun-Chain Yau, Kuo-Tung Tang*, Shuu-Jiun Wang*. A Comparison of Efficacy and Tolerability of New Classes of Migraine-Specific Treatments: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. JAMA Network Open. 2021 (SCI, 2021 IF= 8.48)
26. Chun-Pai Yang#, Bing-Yan Zeng#, Ching-Mao Chang, Po-Hsuan Shih, Cheng-Chia Yang, Ping-Tao Tseng*, Shuu-Jiun Wang*. Comparative effectiveness and tolerability of the pharmacology of monoclonal antibody reacting to calcitonin gene-related peptide for the prevention of chronic migraine: A network meta-analysis of randomized controlled trials. Neurotherapeutics. 2021 (SCI, 2021 IF= 7.620)
27. Yun-Chain Yau#, , Chun-Pai Yang#, Ching-Po Lin, I-Ju Tsai, Ching-Mao Chang, Cheng-Chia Yang, Po-Hsuan Shih, Yin-Yin Liao*. The morphological and dynamic changes of ultrasound in the evaluation of effects of oral steroids treatment for patients with carpal tunnel syndrome. Diagnostics. 2021 (SCI, 2021 IF=3.706)
28. Chun-Pai Yang#, Kuo-Ting Huang#, Ching-Mao Chang, Cheng-Chia Yang, Shuu-liun Wang*. Acute Treatment of Migraine: What has changed in pharmacotherapies? Neurology India. 2021 (SCI, 2021 IF= 2.117)
29. Diem Ngoc Hong Tran, I-Hsuan Hwang, Fun-Jou Chen, Yuan-Pu Tseng, Ching-Mao Chang, Shih-Jen Tsai, Jen-Lin Yang, Ta-Peng Wu, Chung-Hua Hsu, Fang-Pey Chen, Yen-Ying Kung, Core Prescription Pattern of Chinese Herbal Medicine for Depressive Disorders in Taiwan: A Nationwide Population-Based Study, Integrative Medicine Research. 2021 (SCI, 2021 IF= 2.368)
30. 吳璟凰，林虹均，陳國豐，張清貿*. 針刺治療肌少症之文獻回顧與展望. 台灣骨鬆肌少關節防治學會 TBMJ. 2021
31. 馬碩煒，林虹均，曾偉婷，張清貿*. 中藥治療系統性紅斑性狼瘡合併狼瘡腎炎病例報告. 中醫藥雜誌. 2021
32. Gilbert Aaron Lee#, Ching-Mao Chang#, Ying Chieh Wu, Ruo-yu Ma, Cheng-Yu Chen, Yin-Tzu Hsue, Nan-Shih Liao*, Hen-Hong Chang*. Chinese herbal medicine SS-1 inhibits T cell activation and ameliorates TH responses in Sjögren’s syndrome. Journal of the Formosan Medical Association. 2020 (SCI, 2020 IF= 3.008，共同第一作者)
33. Wei-Ting Tseng, Po-Hsuan Shih, Hong-Chun Lin, Pei-Wen Wu, Yen-Ying Kung, Ching-Mao Chang*. Stabilityof a Lupus Nephritis Case after One Year of Integrated Therapy. EC Gastroenterology and Digestive System. 2020 (本論文為先前發表病例報告之後續追蹤[研究發表][臨床病例報告] 中西醫整合治療紅斑性狼瘡腎炎病例報告，Integrated Therapy Improve Urinary Total Protein in Patients with Lupus Nephritis: A Case Report)
34. 吳珮雯，施柏瑄，林虹均，曾偉婷，張清貿*. 臺灣本土治療消化性潰瘍疾病之整合醫學研究回顧. 中醫藥新知. 2020
35. 黃偉勝，林虹均，曾偉婷，張清貿*. 中藥治療修格蘭氏症候群合併系統性紅斑狼瘡病例報告. 中醫藥雜誌. 2020
36. 陳國豐，曾偉婷，林虹均，張清貿*. 中藥緩解修格蘭氏症合併橋本氏甲狀腺炎之病例報告. 中醫藥研究論叢. 2020
37. Ching-Mao Chang#, Po-Hsuan Shih#, Tzeng-Ji Chen, Wen-Chao Ho*, Chun-Pai Yang*. Integrated Therapy Decreases the Mortality of Patients with Polymyositis and Dermatomyositis: A Taiwan-wide Population-Based Retrospective Study. Journal of Ethnopharmacology. 2019, 236: 70-81 (SCI, 2018 IF= 3.414)
38. Chi-Wen Juan#, Ming-Hong Chang, Tsung-Hsing Lin#, Kai-Lin Hwang, Tieh-Cheng Fu, Po-Hsuan Shih, Ching-Mao Chang*, Chun-Pai Yang*. Laser acupuncture for carpal tunnel syndrome: A single-blindedcontrolled study. Journal of Alternative and Complementary Medicine. 2019 (SCI, 2019 IF= 1.868)
39. Ching-Hsiung Liu, Yen-Ying Kung, Tzu-Chen Yeh, Pei-Shan Hsu, Ching-Ju Yang, Chou-Ming Cheng, Hong-Chun Lin, Jen-Lin Yang, Ta-Peng Wu, Ching-Mao Chang, Jen-Chuen Hsieh, Fang-Pey Chen*. Differing Spontaneous Brain Activity in Healthy Adults with Two Different Body Constitutions: A Resting-State Functional Magnetic Resonance Imaging Study. Journal of Clinical Medicine. 2019, 8(7), 951 (SCI, 2018 IF= 5.688)
40. Ching-Hsiung Liu, Yen-Ying Kung, Chun-Liang Lin, Jen-Lin Yang, Ta-Peng Wu, Hong-Chun Lin, Yang-Kai Chang, Ching-Mao Chang, Fang-Pey Chen*. Therapeutic Efficacy and the Impact of the Effect of Acupuncture to Treat Sciatica: A Randomized Controlled Pilot Study. Journal of Pain Research. 2019 (SCI, 2019 IF= 2.236)
41. Pei-Wen Wu#, Po-Hsuan Shih#, Yen-Ying Kung, Fang-Pey Chen, Ching-Mao Chang*. Integrated Therapy Improve Urinary Total Protein in Patients with Lupus Nephritis: A Case Report. Complementary Therapies in Medicine. 2018 (SCI, 2016 IF= 2.013) (本論文後續追蹤持續報告為Stabilityof a Lupus Nephritis Case after One Year of Integrated Therapy. EC Gastroenterology and Digestive System. 2020)
42. Ching-Mao Chang*. Integrated Therapy for Chronic Hepatitis in Taiwan. EC Gastroenterology and Digestive System. 2018
43. Tieh-Cheng Fu, Chaur-Chin Chen, Ching-Mao Chang*, Hen-Hong Chang, Hsueh-Ting Chu*. Analysis of Exercise-induced Periodic Breathing Using an Autoregressive Model and the Hilbert-Huang Transform. Computational and Mathematical Methods in Medicine. 2018 (SCI, 2018 IF= 1.563)
44. Ta-Peng Wu, Cheng-Hung Tsai, Yu-Ting Su, Chu-Chiao Wang, Tzeng-Ji Chen, Ching-Mao Chang, Fang-Pey Chen*. The Evaluation of Professional Divisions of TCM in Taiwan through Patient Visit Records of 2012. International Journal of Environmental Research and Public Health. 2018 (SCI, 2016 IF= 2.145)
45. Ching-Mao Chang, Po-Chang Wu, Jen-Huai Chiang, Yau-Huei Wei, Fang-Pey Chen, Tzeng-Ji Chen, Tai-Long Pan, Hung-Rong Yen* and Hen-Hong Chang*. Integrative therapy decreases the risk of lupus nephritis in patients with systemic lupus erythematosus: A population-based retrospective cohort study. Journal of Ethnopharmacology. 2017 (SCI, 2015 IF= 3.055)
46. Fang-Pey Chen, Ching-Mao Chang, Ta-Peng Wu, Jen-Lin Yang, Yen-Ying Kung, Yi-Hsiang Huang, Chien-Wei Su, Keng-Hsin Lan, Shu-Chiung Chiang and Shinn-Jang Hwang*. Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. Journal of Ethnopharmacology. 2017 (SCI, 2015 IF= 3.055)
47. Yi-Ting Kuo, Hou-Hsun Liao, Jen-Huai Chiang, Bor-Chyuan Chen, Ching-Mao Chang, Ming-Hsien Yeh, Tung-Ti Chang, Mao-Feng Sun, Chia-Chou Yeh, Hung-Rong Yen*. Complementary Chinese Herbal Medicine Therapy Improves Survival of Patients with Pancreatic Cancer in Taiwan: A Nationwide Population-Based Cohort Study. Integrative Cancer Therapies. 2017 (SCI, 2016 IF= 1.923)
48. Shu-Wen Weng, Bor-Chyuan Chen, Yu-Chiao Wang, Chun-Kai Liu, Mao-Feng Sun, Ching-Mao Chang, Jaung-Geng Lin* and Hung-Rong Yen*. Traditional Chinese Medicine Use among Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study. Evidence-Based Complementary and Alternative Medicine. 2016 (SCI, 2015 IF=1.931)
49. Tieh-Cheng Fu, Yi-Chung Lin, Ching-Mao Chang, Wei-Ling Chou, Pei-Hsun Yuan, Min-Hui Liu, Chao-Hung Wang, Juei-Chao Chen, Hen-Hong Chang* and Tai-Long Pan. Validation of a new simple scale to measure symptoms in heart failure from traditional Chinese medicine view: a cross-sectional questionnaire study. BMC Complementary and Alternative Medicine, 2016, 16:342 (SCI, 2015 IF=1.987)
50. Hen-Hong Chang, Shue-Fen Luo, Yin-Tzu Hsue, Ching-Mao Chang, Tzung-Yan Lee, Ming-Ling Hsu, Yu-Chuen Huang, Yu-Jen Chen. Modulation of Endothelial Injury Biomarkers by Traditional Chinese Medicine LC in Systemic Lupus Erythematosus Patients Receiving Standard Treatments. Scientific Reports. 2016 (SCI, 2015 IF=5.578)
51. Tom Fleischer, Tung-Ti Chang, Jen-Huai Chiang, Ching-Mao Chang, Ching-Yun Hsieh, Hung-Rong Yen*. Adjunctive Chinese Herbal Medicine Therapy Improves Survival of Patients with Chronic Myeloid Leukemia: A Nationwide Population-based Cohort Study. Cancer Medicine. 2016 (SCI, 2014 IF=2.5)
52. Ching-Ying Huang, Wan-Yu Lai, Mao-Feng Sun, Che-Chen Lin, Bor-Chyuan Chen, Ching-Mao Chang, Hong-Jen Lin,  Chung-Hsien Yang, Kuo-Chin Huang, Hung-Rong Yen*. Prescription Patterns of Traditional Chinese Medicine for Peptic Ulcer Disease in Taiwan: A Nationwide Population-based Study. Journal of Ethnopharmacology. 2015 (SCI, 2014 IF= 2.998) 
53. Ming-Cheng Huang, Fu-Tzu Paic, Che-Chen Lind, Ching-Mao Chang, Hen-Hong Chang, Yu-Chen Lee, Mao-Feng Sun, Hung-Rong Yen*. Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study. Journal of Ethnopharmacology. 2015 (SCI, 2014 IF= 2.998) 
54. Fang-Pey Chen, Ching-Mao Chang, Jing-Huei Shiu, Jen-Hwey Chiu, Ta-Peng Wu, Jen-Lin Yang, Yen-Ying Kung, Fun-Jou Chen, Chang-Ming Chern* and Shinn-Jang Hwang*: A Clinical Study of Integrating Acupuncture and Western Medicine in Treating Patients with Parkinson's Disease. The American Journal of Chinese Medicine. 2015 (SCI, 2014 IF= 2.625) 
55. Ching-Mao Chang, Hsueh-Ting Chu, Yau-Huei Wei, Fang-Pey Chen, Shengwen Wang, Po-Chang Wu, Hung-Rong Yen, Tzeng-Ji Chen* and Hen-Hong Chang*: The Core Pattern Analysis on Chinese Herbal Medicine for Sjögren's syndrome: A Nationwide Population-Based Study. Scientific Reports. 2015 (SCI, 2014 IF= 5.578) 
56. Fang-Pey Chen, Ching-Mao Chang, Shinn-Jang Hwang*, Yu-Chun Chen and Fun-Jou Chen: Chinese herbal prescriptions for osteoarthritis in Taiwan: analysis of national health insurance dataset. BMC Complementary and Alternative Medicine. 2014 (SCI, 2014 IF=2.020)
57. Ching-Mao Chang, Wen-Hsiang Wu, Benjamin Ing-Tiau Kuo, Tzung-Yan Lee, Chia-Yu Liu, Hen-Hong Chang*: Using A Questionnaire among Patient, Resident Doctor and Senior Supervisor: Are their Answers the Same? Complementary Therapies in Medicine. 2014 (SCI, 2013 IF=2.216)
58. Hsueh-Ting Chu, Han Lin, Theresa Tsun-Hui Tsao, Chun-Fan Chang, William WL Hsiao, Tze-Jung Yeh, Ching-Mao Chang, Yen-Wenn Liu, Tse-Yi Wang, Ko-Chun Yang, Tsung-Jui Chen, Jen-Chih Chen, Kuang-Chi Chen and Cheng-Yan Kao*: Genotyping of human neutrophil antigens (HNA) from whole genome sequencing data. BMC Medical Genomics. 2013 6(31) (SCI, 2013 IF=3.91)
59. Hsueh-Ting Chu, William W. L. Hsiao, Theresa Tsun-Hui Tsao, Ching-Mao Chang, Yen-Wenn Liu, Chen-Chieh Fan, Hen-Hong Chang, Tze-Jung Yeh, Jen-Chih Chen, Chaur-Chin Chen and Cheng-Yan Kao*: Quantitative assessment of mitochondrial DNA copies from whole genome sequencing as a biomarker of aging. BMC Genomics 2012, 13(Suppl 7):S5 (SCI, 2013 IF=4.04)

 
B: Conference Paper

1. 許家豪, 林信華, 顏見明, 林虹均, 吳璟凰, 張清貿*. 滋陰清熱、活血通絡、祛溼化痰治療類風溼性關節炎併發間質性肺炎. 2023年第15屆台北國際中醫藥學術論壇: 2022
2. 李冠宏, 陳國豐, 顏見明, 吳璟凰, 林虹均, 張清貿*. 化瘀祛溼法治療心悸. 2023年第15屆台北國際中醫藥學術論壇: 2022
3. 陳昕元, 吳璟凰, 顏見明, 林虹均, 蘇郁婷, 張清貿*. 修格蘭氏症合併橋本氏甲腺炎患者之中醫舌脈診持續性評估. 2023年第15屆台北國際中醫藥學術論壇: 2022
4. 孔德馨、蘇郁婷、林虹均、陳國豐、張清貿*. 利用中醫舌脈診對修格蘭氏症候群進行持續性評估. 2022年第14屆台北國際中醫藥學術論壇: 2022
5. 吳育瑜、顏見明、林虹均、陳國豐、張清貿*. 清熱除溼、活血通絡、滋養肝腎治療僵直性脊椎炎. 2022年第14屆台北國際中醫藥學術論壇: 2022
6. 洪慈瑩、陳國豐、林虹均、顏見明、張清貿*. 滋陰降火及清熱利溼治療菊地氏病. 2022年第14屆台北國際中醫藥學術論壇: 2022
7. 吳璟凰，曾偉婷，林虹均，陳國豐，張清貿*. 清熱化溼、疏肝健脾、行氣活血治療克隆氏症. 2021年第13屆台北國際中醫藥學術論壇: 2021
8. 黃偉勝, 林虹均, 曾偉婷, 張清貿*: 滋陰潤燥、活血通絡治療修格蘭氏症候群合併身性紅斑狼瘡之病例報告. 2020年第12屆台北國際中醫藥學術論壇: 2020
9. 陳國豐, 曾偉婷, 林虹均, 施柏瑄, 張清貿*: 橋本甲狀腺炎之中醫藥文獻回顧. 2020年第12屆台北國際中醫藥學術論壇: 2020
10. 馬碩煒, 曾偉婷, 林虹均, 張清貿*: 祛風除濕、清熱育陰、活血化瘀治療系統性紅斑性狼瘡合併狼瘡腎炎. 2020年第12屆台北國際中醫藥學術論壇: 2020
11. 林虹均, 施柏瑄, 朱學亭, 曹榮穎, 陳方佩, 張清貿*: 利用數學模式分析方法探討歷代艾附暖宮丸同名方劑之異同性. 2018年第10屆台北國際中醫藥學術論壇: 2018
12. 張卜云, 施柏瑄, 龔彥穎, 謝承運, 曾元卜, 陳方佩, 張清貿*: 中醫藥治療血管炎之文獻回顧. 2018年第10屆台北國際中醫藥學術論壇: 2018
13. 曾偉婷, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*: 影響生長相關激素之中藥探討. 2018年第10屆台北國際中醫藥學術論壇: 2018
14. 孫彩霞, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*: 中醫輔助治療類肉瘤症病例報告. 2018年第10屆台北國際中醫藥學術論壇: 2018
15. 廖雅嫻, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*. 木防己湯緩解類風濕性關節炎患者之主動脈辦狹窄. 2018年第10屆台北國際中醫藥學術論壇: 2018
16. 蘇郁婷, 蔡承宏, 陳方佩, 陳曾基, 張清貿, 王楚嶠, 吳大鵬*: 臺灣中醫專科醫師制度之趨勢探討. 2018年第10屆台北國際中醫藥學術論壇: 2018
17. 張凱惟, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎, 張清貿*,各國藥典對三七品質管制比較, 2017年第9屆台北國際中醫藥學術論壇: 2017
18. 張雅婷, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*, 抗凝血劑與中藥併用產生不良反應風險之文獻回顧, 2017年第9屆台北國際中醫藥學術論壇: 2017
19. 張毓庭, 張清貿, 陳方佩, 龔彥穎, 楊仁鄰, 吳大鵬*, 針刺治療腦膜瘤術後神經學症狀病例報告, 2017年第9屆台北國際中醫藥學術論壇: 2017
20. 吳珮雯, 張清貿, 陳方佩, 楊仁鄰, 龔彥穎*, 突發性感覺神經性耳聾之中醫針灸治療現況文獻回顧, 2017年第9屆台北國際中醫藥學術論壇: 2017
21. 林奇玄, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*, 臺灣孕婦禁忌中藥之安全性探討-文獻回顧與分析, 2017年第9屆台北國際中醫藥學術論壇: 2017
22. 張嘉芸, 張清貿, 陳方佩, 龔彥穎, 楊仁鄰, 吳大鵬*, 中西醫結合治療頭頸癌放射線治療後下頷骨壞死病例報告, 2017年第9屆台北國際中醫藥學術論壇: 2017
23. Ching-Mao Chang, Po-Hsuan Shih, Shengwen Wang, Hen-Hong Chang, Fang-Pey Chen, Hsueh-Ting Chu*, A Wiki-Based Traditional Chinese Medicine Formulary Knowledge System for Comparative Herb-Drug Interaction and Formula Zheng Analysis, The 17th International Congress of Oriental Medicine (ICOM): 2014
24. Ching-Mao Chang, Hsueh-Ting Chu, Yau-Huei Wei, Fang-Pey Chen, Shengwen Wang, Po-Chang Wu, Hung-Rong Yen, Tzeng-Ji Chen*, Hen-Hong Chang*, The Core Pattern of Chinese Herbal Medicines for Sjögren's Syndrome in Taiwan from National Health Insurance Research Database between year 2002 to 2011, 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2014
25. Ching-Mao Chang, Yi-Chung Ling, Po-Chang Wu, Hen-Hong Chang*, The Change of Symptoms in the Treatment of Traditional Chinese Medicine for Systemic Lupus Erythematosus, 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2014
26. Tieh-Cheng Fu, Yi-Chung Ling, Wei-Ling Chou, Ching-Mao Chang, Jong-Shyan Wang*, Hen-Hong Chang*, The Application of TCM Inquiry Diagnosis in the Functional Classification of Heart Failure, 13th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2014
27. Yu-Yun Huang, Fang-Pey Chen*, Shinn-Jang Hwang, Maw-Shiou Jong, Fun-Jou Chen, Yi-Tsau Huang, Ching-Mao Chang, Potential Herb-Drug Interaction between Ginseng and Western Medicine in Taiwan: Analysis of National Health Insurance Dataset, International Conference of Traditional and Complementary Medicine on Health (ICTCMH): 2013 
28. Ching-Mao Chang, Tin-Yun Ho, Po-Hsuan Shih, Hsueh-Ting Chu*, An Online Platform for Multiple Factors Analysis of Traditional Chinese Medicine, 2012 Cloud Computing Workshop (2012 CCW): 2012
29. Dun-Ming Huang, Hsueh-Ting Chu, Ching-Mao Chang and Cheng-Yan Kao*: Epitope Prediction for Multi-epitope HCA661 Liver Cancer Vaccines. World Congress on Engineering and Computer Science: 2012
30. Ching-Mao Chang, Benjamin Ing-Tiau Kuo, Wen-Hsiang Wu, Chia-Yu Liu, Hen-Hong Chang*: The Consistency Among Patients, Resident Doctor and Senior Supervisor in using a Traditional Chinese Medicine Questionnaire. 10th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2011
31. Ching-Mao Chang, Horng-Sheng Shiue, Yun-Shien Lee, Li-Tzu Chin, Hen-Hong Chang*: The effect of herbal paste treatment on patients with Allergic Rhinitis. 10th Meeting of Consortium for Globalization of Chinese Medicine (CGCM): 2011
32. Ching-Mao Chang, Hsueh-Ting Chu, Chia-Cheng Lee, Hsin-Yi Lo, Jaw-Chyun Chen, Chien-Yun Hsiang, Chang,Yung-Hsien, Tin-Yun Ho*: HerbBlast - A program for similarity and ontology analysis of Chinese herbal medicine. Bioinformatics in Taiwan: 2006

C：專書

1. Pin-Chung Huang, Fu-Chi Yang, Ching-Mao Chang, Chun-Pai Yang*. Chapter 4: Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. Update on Emerging Treatments for Migraine, Elsevier: Progress in Brain Research (ISBN: 978-0-12-821108-3), 2020(255):P.99-P.121

D: 中醫論述

1. 張凱惟, 張清貿, 陳方佩, 龔彥穎*. 中醫治療主動脈瓣狹窄病例之理論與病例報告. 中醫藥研究論叢. 2018, 21(1): 171-190 (in Chinese)
2. 張凱惟, 施柏瑄, 謝承運, 曾元卜, 陳方佩, 龔彥穎, 張清貿*. 各國中草藥質量標準比較：以藥材三七為例. 台北市中醫醫學雜誌. 2017 (in Chinese)
3. 張清貿#, 施柏瑄#, 楊仕哲*. 心腦主神明學說的沿革. 中醫藥雜誌. 2017, 28(1): 2801001
4. 施柏瑄#, 洪國棟#, 林奕中, 張清貿*. 僵直性脊椎炎之中醫藥文獻回顧. 中醫藥研究論叢. 2016, 19(2):99-112
5. 張清貿. 食療在中醫兒科的應用, 榮總人. 2016 (33): 3
6. 謝承運, 張清貿, 陳方佩, 吳大鵬, 楊仁鄰, 龔彥穎*. 雷諾氏症候群的中醫診治病例報告. 北市中醫會刊. 2016, 22(1): 55-64
7. 蔡承宏, 張清貿, 龔彥穎, 陳方佩, 吳大鵬*. 針刺治療嬰兒臂神經叢麻痺. 臺灣中醫醫學雜誌. 2015, 13(2): 13-24
8. 蔡承宏, 張清貿, 龔彥穎, 陳方佩, 吳大鵬*. 針刺緩解粒線體疾病病童疑似肌陣攣發作之病例報告. 中醫藥研究論叢. 2015, 18(2): 117-127
9. 張清貿, 施柏瑄. 從中醫觀點看產後調理, 榮總人. 2014 (31): 6
10. 張清貿, 施柏瑄, 朱學亭, 陳方佩. 該如何理解「證」？- 中醫證型現代研究的定性與定量, 臨床醫學. 2014 (73)：189-195
11. 張清貿, 侯庭鏞, 朱學亭, 李佳橙, 張永賢* 附子在溫經散寒及清熱瀉火劑之數學模式表現 (A mathematical method to differentiate the effects of “Aconitum carmichaeli Debx” in different prescriptions). Mid-Taiwan Journal of Medicine. 2008 13(3): 152-157

E: 研究計畫

1. 利用口腔微生物菌相探討針刺風池穴合併攢竹穴治療乾眼症與修格蘭氏症口眼乾燥症狀之立即性與長期性治療效果 (111-2320-B-075 -006 -MY2)，主持人，2022.08~2024.07，科技部計畫，ClinicalTrials.gov：NCT04877483
2. 利用DNA Exome sequencing技術探索修格蘭氏症之基因序列與中醫體質、舌診、脈診之相關性研究 (第二年：整合功能性蛋白質體學及口腔微生物菌相) (V109B-034)，主持人，2020.01~2020.12，臺北榮民總醫院院內計畫，ClinicalTrials.gov：NCT03935373
3. 利用DNA Exome sequencing技術探索修格蘭氏症(Sjögren's syndrome)之基因序列與中醫體質、舌診、脈診之相關性研究(V108B-031)，主持人，2019.01~2019.12，臺北榮民總醫院院內計畫，ClinicalTrials.gov：NCT03935373
4. 利用IFN-γ誘導人類下顎唾液腺細胞模型探討修格蘭氏症中醫健保資料庫前十大中藥單方之粒線體抗氧化機轉(V106A-006)，主持人，2017.01~2017.12，臺北榮民總醫院院內計畫
5. 生物資訊在傷寒方的應用 - 傷寒方組方邏輯之探討 (NSC97-2815-C-039-061-B)，大專生專題計畫專題生，2008.07~2009.02，國科會

F: 參與研究計畫

1. 中藥複方SS-1對乾燥症之隨機雙盲臨床試驗及其作用機轉之研究 (MOST 103-2325-B-182-010、MOST 104-2325-B-039-003)，博士生協同研究人員，2014.02~2016.07 (預定)，科技部(生技醫藥國家型研究計畫)  (NCT02110446)
2. Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome, ClinicalTrials.gov: NCT02110446
3. 中藥複方SS-1治療乾燥症之免疫基因調控機轉研究 (MOST 105-2325-B-039-006)，博士生協同研究人員，2016.05~2016.04 (預定)，科技部(生技醫藥國家型研究計畫)  (NCT02855658)
4. Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren’s Syndrome, ClinicalTrials.gov: NCT02855658

中藥複方SS-1對乾燥症之隨機雙盲臨床試驗及其作用機轉之研究

摘要

目的：探討中藥複方SS-1對修格蘭氏症/乾燥症 (Sjögren's syndrome, SJS)患者之療效

方法：

本研究希望藉由隨機雙盲對照交叉設計之臨床試驗，探討中藥複方SS-1治療修格蘭氏症/乾燥症 (Sjögren's syndrome)之抗氧化之能力及調控與氧化壓力相關之cytokines表現，並希望藉由降低氧化壓力觀察到生活品質提昇及臨床症狀減輕等效果。同時也希望藉由細胞實驗，觀察SS-1抗氧化之能力，並從細胞實驗中以Cytokine Assays kit分析套組研究氧化壓力下cytokine被調控的情形，藉以了解SS-1抗氧化之機轉。最後再從受到顯著調控之cytokine篩選出SS-1組成之單方(中藥)，建立初步篩選機制。

本研究為兩年期基礎及臨床試驗研究計畫，研究設計為隨機、雙盲、安慰劑對照、交叉設計之臨床試驗，收案患者依亂數表隨機分派為A、B兩組，兩組各篩選45人，進入試驗各30人，A組先服用試驗用藥SS-1，B組先服用試驗用藥placebo (玉米澱粉加1/100劑量SS-1)，治療三個月後中斷服藥1個月進行washout後，將A、B兩組藥物交換再治療三個月，最後評估SS-1兩組治療之療效，研究中兩組均維持原有西醫穩定之治療。本臨床試驗用藥SS-1複方，受試者每日三次口服試驗用藥，每次服用6公克，治療12週，停藥4週後，兩組交換，依前述流程再治療12週，總試驗時間共28週。主要評估時間點為治療前(V1)，治療12週後(V2)，crossover治療前(V3)，crossover治療12週後(V4)，終止試驗的條件為收案完成或發生嚴重藥物不良反應。

預期成果：

1. 評估中藥SS-1改善修格蘭氏症/乾燥症 (Sjögren's syndrome)患者臨床症狀及改善生活品質之效果。 
2. 探討中醫舌診在SS-1治療修格蘭氏症/乾燥症 (Sjögren's syndrome)患者前後之變化。 
3. 評估中藥SS-1降低修格蘭氏症/乾燥症 (Sjögren's syndrome)患者體內氧化壓力之效果，是否可提高血漿中TAC和白血球內mtDNA copy number含量及抗氧化酵素包括SOD、GPX和CAT的表現量，並降低血漿中8-OHdG的含量及白血球細胞內粒線體DNA 4,977 bp缺失的突變比例。 
4. 評估中藥SS-1調控修格蘭氏症/乾燥症 (Sjögren's syndrome)患者血液內Cytokine之表現及免疫功能之變化。 
5. 探討中藥SS-1在IFN-γ及IFN-α誘發人類下顎唾液腺細胞(submaxillary salivary gland, A-253細胞株)改善細胞內氧化壓力、降低Cytokine表現、調控免疫細胞能力及其分子機轉。 
6. 選擇臨床檢體及細胞實驗中觀察到受顯著調控之ROS及cytokine，並初步建立SJS之中藥篩選機制，以提供實證醫學之證據。

關鍵字：乾燥症、甘露飲、桑菊飲、血府逐瘀湯、氧化壓力、免疫調節

Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome

Abstract

Objective: To evaluate the efficacy of Chinese herbal medicine (SS-1) for the Sjögren’s syndrome (SJS) patients.

Method: 

We take a randomized, double-blinded, placebo-controlled, cross-over design clinical trial to evaluate the effect of Chinese herbal medicine (SS-1) on the regulation of oxidative-related cytokines and the antioxidant capacity for the Sjögren’s syndrome (SJS) patients. Through the oxidative stress reduction, the quality of life and clinical manifestation will be improved. We will also use a SJS cell model to elucidate the antioxidant mechanism of SS-1.

The SJS patients in this clinical trial will be screened and be referred from the out-patient department (OPD) of the Rheumatology Department of Chang Gung Memorial Hospital. The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD.  Group A patients will receive 12 weeks SS-1 treatment first and stop the SS-1 for 4 weeks to enter the wash-out phase, and then receive 12weeks placebo treatment after the wash-out phase. Group B patients receive 12 weeks placebo first and stop the placebo treatment for 4 weeks to enter the wash-out phase, and then receive 12 weeks SS-1 treatment after the wash-out phase. Patients in both groups take 6 gram of experiment medicine three times per day. We plan to evaluate the associated parameters at the time just before treatment (V1), after treatment for 12weeks (V2), at the end of wash-out phase (V3) and when the crossover treatment is completed (V4).

Expected Results:

1. SS-1 may improve the clinical manifestation and quality of life for the patients with Sjögren’s syndrome. 
2. To evaluate the effect of the Chinese medicine on the tongue diagnosis before and after treatment. 
3. SS-1 may reduce the oxidative stress (8-OHdG and mtDNA 4977 bp deletion) and elevate the antioxidant capacity (TAC , mtDNA copy number, SOD, GPX, CAT). 
4. SS-1 may have the regulatory effect on cytokine secretion and immune function. 
5. SS-1 may have the capacity of reducing the oxidative stress, elevating the antioxidant capacity and regulating the immune response in the model of submaxillary salivary gland cell line with the induction of IFN-γand IFN-α. 
6. Identification of the single herb in the SS-1 mixture that regulates oxidative stress and cytokine and set up of the Chinese herbs screen platform for Sjögren’s syndrome.

Keyword: Sjögren’s syndrome, Gan-Lu-Yin, Sang-Ju-Yin, Xuefu-Zhuyu-Decoction, Oxidative stress, Immune regulation

------------------------------------------------------------------------------------------------------

中藥複方SS-1治療乾燥症之免疫基因調控機轉研究

摘要

目的：探討中藥複方SS-1治療乾燥症Sjögren's syndrome之免疫基因調控機轉

方法：

本研究前期完成之隨機雙盲對照雙中心臨床試驗可提供中藥複方SS-1調控氧化壓力及cytokine之療效證據，但前期尚無探討到基因調控，也無建立SS-1之健康對照組。因此本研究擬建立健康對照組之氧化壓力與細胞激素(Cytokines)正常值，藉以和SS-1前期臨床試驗收案之72位受試者做比較，並希望藉由Nanostring nCounter immune Panel探討770個免疫相關之基因調控，分析比較「治療前後療效最佳SS-1受試者」至少20名及「健康對照組」至少10名之間的免疫相關基因調控表現，希望能藉此了解受試者臨床症狀、氧化壓力指標與Cytokine指標是如何被基因調控。

預期成果：

1.          建立健康對照組受試者之檢體ROS與cytokines正常值。

2.          分析比較SS-1受試者與健康對照組受試者之檢體ROS與cytokines表現。

3.          評估中藥SS-1調控乾燥症患者檢體之免疫相關基因表現。

4.          分析比較治療前後療效最佳SS-1受試者及健康對照組受試者兩組之檢體的770項免疫相關基因之表現。

5.          分析比較中醫舌診與770個免疫相關基因表現之相關性。

6.          綜合分析臨床指標、臨床問卷及免疫相關基因之相關性。

關鍵字：乾燥症、甘露飲、桑菊飲、血府逐瘀湯、氧化壓力、免疫調節、基因調控

Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren’s Syndrome

Abstract

Objective: To evaluate the modulation of immunity-related gene expression for the Sjögren’s syndrome under Chinese herbal medicine (SS-1) treatment.

Method: 

The evidence of the regulation of oxidative-related cytokines and the antioxidant capacity could be provided from the previous randomized, double-blinded, placebo-controlled, cross-over design, two-center clinical trial for evaluating the effect of Chinese herbal medicine (SS-1) for the Sjögren’s syndrome patients. However, we could not find out the modulation of immunity-related gene expression for SS-1 treatment, and it did set up a healthy control group for SS-1 comparison. We want to establish a healthy control group for evaluating the normal range of oxidative stress and cytokines, which this work could be used to compare with the 72 SS-1 subjects in previous study. And we also want use Nanostring nCounter immune Panel to analyze the 770 immunity-related gene expression for the Sjögren’s syndrome under the SS-1 treatment: (1) The best 10 (at least) efficacy SJS subjects who were evaluated before and after SS-1 treatments. (2) The 10 (at least) healthy control subjects. The findings could provide the evidence on the modulation of immunity-related gene expression for clinical manifestation, oxidative stress and cytokine in Sjögren’s syndrome patients.

Expected Results:

1.          Establish the normal range of oxidative stress and cytokines for healthy control group.

2.          To evaluate the regulatory effect on oxidative stress and cytokine secretion between SS-1 group and healthy control group.

3.          To evaluate the immunity-related gene expression for the Sjögren’s syndrome under the SS-1 treatment.

4.          To evaluate the immunity-related gene expression among the best efficacy SJS subjects and healthy control subjects.

5.          To evaluate the immunity-related gene expression with the characteristic of TCM tongue diagnosis.

6.          To analyze the correlation among clinical manifestations, Sjögren’s syndrome -related clinical questionnaires and immunity-related gene expression.

Keyword: Sjögren’s syndrome, Gan-Lu-Yin, Sang-Ju-Yin, Xuefu-Zhuyu-Decoction, Oxidative stress, Immune regulation, Gene modulation

G: 博士論文  (2012-2017，2014/06/13通過資格考成為博士候選人，2017/07通過博士學位考試，並取得臨床醫學博士學位)

<中藥臨床試驗暨轉譯醫學研究>

• 中文：中藥複方治療修格蘭氏症之療效評估及其抗氧化與免疫調控機轉之研究
• 英文：The Efficacy of Chinese Herbal Formula on Sjögren's syndrome and its Mechanism of Anti-oxidative and Immune Modulatory Effects